Trajan Group (ASX:TRJ): Could Australia’s Infrastructure and Capex Cycle Power the Next Re-Rating?

Aditi Sarkar

02 September 2026 04:08 PM AEST

Trajan Group (ASX:TRJ): Could Australia’s Infrastructure and Capex Cycle Power the Next Re-Rating?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Trajan Group Holdings develops analytical and life-sciences products used across healthcare, food and environmental testing markets.
FY26 Revenue declined as weaker laboratory Capital spending affected equipment-related sales.
Second-half Margin improvement highlighted the impact of cost reduction initiatives.
Future performance depends on laboratory Investment recovery, Recurring Revenue growth and FY27 execution.

Trajan Group Holdings (ASX:TRJ) is an Australian-headquartered developer and manufacturer of analytical and life-sciences products used in laboratories globally. Its products support applications across areas including human health testing, food analysis and environmental monitoring.

The company’s performance is closely linked to global scientific research activity, laboratory investment cycles and Demand for analytical equipment and consumables. Following the FY26 result, investors are assessing whether improving margins and a potential recovery in laboratory capital spending can support the next phase of growth.

Latest Development

Trajan Group Holdings (ASX:TRJ) released its FY26 full-year results on 27 August 2026. Group revenue was A$161.4 million, down 3.1% from the previous year, while normalised EBITDA declined 14.7% to A$13.2 million.

The company reported a stronger second-half performance, with normalised EBITDA reaching A$8.1 million compared with a weaker first half. Second-half pro forma gross margin improved from 37.4% to 40.6%.

Management highlighted foreign exchange impacts, weaker North American capital-equipment funding conditions and the loss of Certus-related revenue as key factors affecting FY26 performance. The company positioned FY27 as a year focused on recovery through cost improvements and growth initiatives.

Financial Performance

The FY26 result showed a mixed performance for Trajan Group Holdings (ASX:TRJ), with softer revenue offset by improving operational efficiency during the second half.

The decline in revenue was primarily concentrated in capital-equipment sales, which are more sensitive to changes in research funding and laboratory investment cycles. The improvement in gross margins during the second half indicated that cost-management initiatives were beginning to support profitability.

For FY27, the company expects mid-single-digit organic revenue growth and double-digit EBITDA growth, supported by a lower cost base and improving operating conditions.

The removal of certain revenue pressures, including Certus-related impacts, and the focus on expanding recurring consumables revenue remain important elements of the company’s strategy.

Growth Drivers

The recovery of North American laboratory and life-sciences Capital Expenditure remains a key Factor for Trajan Group Holdings (ASX:TRJ). A stronger investment environment could support demand for the company’s analytical products and improve revenue momentum.

Execution against FY27 guidance, continued margin improvement and increasing contribution from recurring consumables revenue will be important indicators for investors.

The company’s product development initiatives and potential expansion opportunities could also support longer-term growth by strengthening its position in specialised laboratory markets.

Key Risks

Trajan Group Holdings (ASX:TRJ) generates a significant portion of its revenue internationally, making reported financial performance sensitive to currency movements.

Demand for laboratory capital equipment remains influenced by external factors such as research funding availability and broader economic conditions. A slower recovery in laboratory investment could affect the company’s growth expectations.

The company also faces execution risks associated with cost reduction programs, Acquisition integration and maintaining revenue momentum across its product portfolio.

Investor Outlook

Trajan Group Holdings (ASX:TRJ) enters FY27 with a focus on converting operational improvements into renewed Earnings growth. The FY26 result highlighted a stronger second half, improved margins and a recovery strategy centred on cost discipline and market conditions.

The company’s future performance will depend on the pace of recovery in laboratory capital spending, delivery against FY27 guidance and continued progress in higher-margin recurring revenue streams.

FAQs

Q: What does Trajan Group Holdings do?

A:Trajan Group Holdings develops analytical and life-sciences products used in laboratory applications.

Q: What affected Trajan’s FY26 performance?

A:Weaker laboratory capital spending, foreign exchange impacts and the loss of Certus-related revenue affected FY26 results.

Q: What is Trajan’s FY27 outlook?

A:The company expects mid-single-digit organic revenue growth and double-digit EBITDA growth.

Q: What are the key growth drivers for Trajan?

A:Recovery in laboratory spending, recurring consumables growth and margin improvement are key drivers.

Q: What are the main risks for Trajan Group Holdings?

A:Key risks include capital expenditure cycles, currency movements, execution challenges and slower market recovery.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.